He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.
His laboratory is focusing on elucidating molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways. He works with scientists engaged in molecular target identification and chemists whose remit is to target specific signalling abnormalities to develop novel therapies for breast cancer. He also runs a translational laboratory which focuses on detection of micrometastatic disease and application to the treatment of breast cancer. He is Chairman of the International Collaborative Cancer Group. This is a multinational trial centre which is based within Imperial College focussing on phase II and phase III studies in breast cancer.